Effect of Vitamin D and Zinc Supplementation on Inflammatory Biomarkers in Pulmonary Tuberculosis Patients

Other illness

• Patients with extra-pulmonary tuberculosis without lung involvement, or patients with suspected or confirmed MDR-TB/XDR-TB.
• Severe liver failure or end-stage renal disease requiring chronic dialysis.
• Patients taking systemic immunosuppressive drugs (e.g., prednisone equivalent \>10 mg/day for \>= 14 days), active chemotherapy, or active unstable autoimmune disease.
• Patients with severe uncontrolled co-infections (e.g., sepsis, severe non-TB pneumonia) at the time of screening.
• Patients with known allergy or hypersensitivity to cholecalciferol or zinc preparations used in this study.

Lab values

• Patients with diseases or conditions that alter vitamin D or calcium metabolism, such as hypercalcemia (total calcium \>= 10.5 mg/dL), hyperparathyroidism, or a history of recurrent calcium nephrolitiasis.

Other

• Pregnant or breastfeeding women.
• Patients unable to follow the follow-up schedules or considered likely to drop out based on investigator's assessment.

• Adult patients aged 18 years or older.
• Active pulmonary tuberculosis confirmed by positive acid-fast bacilli (AFB) sputum smear or positive molecular rapid test (GeneXpert/TCM), diagnosed by a pulmonologist.
• Currently undergoing the intensive phase of anti-tuberculosis therapy (ATT), with the duration of ATT treatment less than 14 days since initiation at the time of recruitment.
• Patients with vitamin D deficiency or insufficiency and zinc deficiency.
• Patient is willing to follow all study procedures for 8 weeks and signed the written informed consent.
• Patients who have not consumed vitamin D and/or zinc supplements within the last 30 days (wash-out period).